Open AccessGiant cell arteritis treatment patterns and rates of serious infections
Author(s) -
Sara K. Tedeschi,
Yinzhu Jin,
Seanna Vine,
Hemin Lee,
Attila Pethoe-Schramm,
Vincent Yau,
Seoyoung Kim
Publication year - 2021
Publication title -
clinical and experimental rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.184
H-Index - 95
eISSN - 1593-098X
pISSN - 0392-856X
DOI - 10.55563/clinexprheumatol/uonz1p
Subject(s) - medicine , giant cell arteritis , hazard ratio , cohort , comorbidity , prednisone , tocilizumab , proportional hazards model , incidence (geometry) , hydroxychloroquine , rheumatoid arthritis , vasculitis , confidence interval , disease , physics , optics , covid-19 , infectious disease (medical specialty)
Giant cell arteritis (GCA) afflicts older adults who may have age- and comorbidity-related risks for infection and is treated with immunosuppressants that increase risk of infection. We examined GCA treatment patterns and rates of serious infections in two real-world cohorts in the U.S.